OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
France Targets Shein, Temu With Fast-Fashion Fees 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Add as a preferred source on Google
Dublin, March 09, 2018 -- The "Global Sexual Health Partnering 2012-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
Global Sexual Health Partnering 2012 to 2018 provides the full collection of Sexual Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Sexual Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Sexual Health deals.
The report presents financial deal terms values for Sexual Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In addition, a comprehensive appendix is provided with each report of all Sexual Health partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Report scope
Global Sexual Health Partnering 2012 to 2018 includes:
- Trends in Sexual Health dealmaking in the biopharma industry since 2012
- Analysis of Sexual Health deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Sexual Health deal contract documents
- Comprehensive access to over 3500 Sexual Health deal records
- The leading Sexual Health deals by value since 2012
- Most active Sexual Health dealmakers since 2012
Available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Sexual Health dealmaking
Chapter 3 - Financial deal terms for Sexual Health partnering
Chapter 4 - Leading Sexual Health deals and dealmakers
Chapter 5 - Sexual Health contract document directory
Chapter 6 - Sexual Health dealmaking by therapeutic target
For more information about this report visit https://www.researchandmarkets.com/research/qrzn88/global_sexual?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Sexual and Reproductive Health Drugs
